cabazitaxel

Cabazitaxel is a second-generation, semi-synthetic taxane antineoplastic agent used in combination with corticosteroids (such as prednisone) to treat metastatic castration-resistant prostate cancer in patients previously treated with a docetaxel-containing regimen. It acts as a microtubule inhibitor by binding to the N-terminal amino acids of the beta-tubulin subunit, promoting microtubule polymerization and inhibiting disassembly. This stabilizes microtubules, blocks mitotic and interphase cellular functions, arrests tumor cell cycle progression, and induces tumor cell death. Cabazitaxel has low affinity for the P-glycoprotein efflux pump compared to other taxanes like paclitaxel and docetaxel, allowing it to overcome certain drug resistance mechanisms and penetrate the blood–brain barrier more effectively. It was developed as an option for patients whose prostate cancer has progressed despite prior chemotherapy[1][2][5][6].

Brand names

Jevtana

Other names

cabazitaxelXRP6258XRP-6258XRP 6258